Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Non-GLP Exploratory Toxicology

At Sygnature Discovery, our experienced and skilled teams have access to the latest technology that can make a difference to our clients by designing time- and cost-effective strategies for early toxicology assessment of a compound or compound series.

These strategies mitigate risks earlier and before a compound enters pre-clinical development. Importantly the information obtained can be rapidly used to engineer out toxicological liabilities and accelerate the route to the clinic.

Early, exploratory safety assessment usually includes pharmacology studies, general toxicity studies, toxicokinetic and nonclinical pharmacokinetic studies, reproduction toxicity studies, cardiotoxicity and genotoxicity studies and, for drugs that have special cause for concern or are intended for a long duration of use, an assessment of carcinogenic potential.

Early assessment of drug safety risk in pre-clinical models

  • Exposure, toxicokinetics and tolerability studies including safety pharmacology/safety margin (MTD, NOAEL).
  • Dose range finding studies. Dose-escalation studies or short-duration dose-ranging studies define an MTD in the general toxicity test species.
  • Formulation assessment.
  • Tissue analysis.

In vitro metabolic and plasma protein binding data for animals and humans and systemic exposure data in the species used for repeated-dose toxicity studies should be evaluated.

Mechanistic toxicology studies

Drug-Drug Interactions (DDI) risk assessment

Drug-drug interactions (DDI) refer to simultaneously administered drugs that interfere with each other’s absorption, distribution, metabolism, and elimination (ADME).

Proof of concept for drug mechanism of action or efficacy

Our streamlined procedures and targeted reports allow us to offer credible data with operationally efficient services. Working with Sygnature Discovery will enable you to incorporate the industry’s best practices into your drug testing program.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.